XML 63 R46.htm IDEA: XBRL DOCUMENT v3.24.3
Significant Agreements – Related Parties (Details) - USD ($)
1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Jul. 24, 2020
Jul. 23, 2019
Sep. 30, 2021
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Dec. 31, 2022
Dec. 31, 2023
Related Party Transaction [Line Items]                  
Research and development       $ 15,900,000 $ 6,900,000 $ 43,700,000 $ 20,100,000    
Current liabilities       14,481,000   14,481,000     $ 15,085,000
Prepaid expenses and other assets       756,000   756,000     633,000
Other assets       2,115,000   2,115,000     2,094,000
Related Party                  
Related Party Transaction [Line Items]                  
Research and development       2,310,000 2,271,000 7,400,000 6,511,000    
Accrued expenses and other current liabilities       1,801,000   1,801,000     3,561,000
Accounts payable       431,000   431,000     1,044,000
Master Services Agreement | Related Party                  
Related Party Transaction [Line Items]                  
Research and development       0 0 0 0    
Accrued expenses and other current liabilities       0.0   0.0     1,600,000
BBL Agreements | Related Party                  
Related Party Transaction [Line Items]                  
Research and development       700,000 300,000 1,100,000 700,000    
Accrued expenses and other current liabilities       1,100,000   1,100,000     1,700,000
Related party agreement, term   5 years              
Syngene Agreement, Manufacturing | Related Party                  
Related Party Transaction [Line Items]                  
Related party agreement, term   6 years              
Syngene Agreement, Master Contract Services | Related Party                  
Related Party Transaction [Line Items]                  
Related party agreement, term 2 years                
Syngene Agreements | Related Party                  
Related Party Transaction [Line Items]                  
Research and development       2,000,000.0 $ 1,600,000 6,300,000 $ 5,800,000    
Accrued expenses and other current liabilities       800,000   800,000     1,900,000
Current liabilities       1,200,000   1,200,000     2,900,000
Accounts payable       $ 400,000   $ 400,000     1,000,000.0
Biofusion Agreement | Related Party                  
Related Party Transaction [Line Items]                  
Research and development               $ 4,100,000  
Accrued expenses and other current liabilities               $ 7,700,000  
Promissory Note | Chief Financial Officer                  
Related Party Transaction [Line Items]                  
Promissory note loan amount     $ 274,000            
Interest rate     0.86%            
Number of shares pledged as collateral (in shares)     616,320            
Prepaid expenses and other assets                 68,000
Other assets                 $ 68,000